Survival-inferred fragility index of FDA-approved cancer drugs using surrogate endpoints

被引:0
|
作者
Ofer, Jonathan
Gilboa, Shai
Pras, Yarden
Markel, Gal
Bomze, David
Meirson, Tomer
机构
[1] Beilinson Med Ctr, Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1573
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
    Whitehead, Clarissa A.
    Nguyen, Hong P. T.
    Morokoff, Andrew P.
    Luwor, Rodney B.
    Paradiso, Lucia
    Kaye, Andrew H.
    Mantamadiotis, Theo
    Stylli, Stanley S.
    TRANSLATIONAL ONCOLOGY, 2018, 11 (06): : 1406 - 1418
  • [42] Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice
    Andrew C. Y. Lee
    Kelvin K. W. To
    Anna J. X. Zhang
    Houshun Zhu
    Can Li
    Ricky R. Zhang
    Ivan F. N. Hung
    Richard Y. T. Kao
    Kwok-Hung Chan
    Kwok-Yung Yuen
    Archives of Virology, 2018, 163 : 2349 - 2358
  • [43] Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice
    Lee, Andrew C. Y.
    To, Kelvin K. W.
    Zhang, Anna J. X.
    Zhu, Houshun
    Li, Can
    Zhang, Ricky R.
    Hung, Ivan F. N.
    Kao, Richard Y. T.
    Chan, Kwok-Hung
    Yuen, Kwok-Yung
    ARCHIVES OF VIROLOGY, 2018, 163 (09) : 2349 - 2358
  • [44] Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
    Taylor, David J.
    Parsons, Christine E.
    Han, Haiyong
    Jayaraman, Arul
    Rege, Kaushal
    BMC CANCER, 2011, 11
  • [45] Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
    David J Taylor
    Christine E Parsons
    Haiyong Han
    Arul Jayaraman
    Kaushal Rege
    BMC Cancer, 11
  • [46] Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
    Tay-Teo, Kiu
    Ilbawi, Andre
    Hill, Suzanne R.
    JAMA NETWORK OPEN, 2019, 2 (01) : e186875
  • [47] Virtual Screening Approach to Repurpose FDA-approved Drugs for Targeting Acid Ceramidase-1 in Pancreatic Cancer
    Raval, Nipam
    Henrichs, Grant
    FASEB JOURNAL, 2022, 36
  • [48] Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts
    Bharate, Sonali S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 607
  • [49] Discovery of FDA-Approved Drugs as Inhibitors of Fatty Acid Binding Protein 4 Using Molecular Docking Screening
    Wang, Yan
    Law, Wai-Kit
    Hu, Jian-Shu
    Lin, Huang-Quan
    Ip, Tsz-Ming
    Wan, David Chi-Cheong
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2014, 54 (11) : 3046 - 3050
  • [50] DISCOVERY OF DRUGS THAT PROMOTE THE PHAGOCYTIC ABILITY OF MACROPHAGES TO CALCIUM OXALATE CRYSTALS USING THE FDA-APPROVED DRUG LIBRARY
    Okada, Atsushi
    Takase, Hiroshi
    Isogai, Masahiko
    Okada, Tomoki
    Hattori, Tatsuya
    Chaya, Ryosuke
    Kawase, Kengo
    Tanaka, Yutaro
    Kato, Taiki
    Sugino, Teruaki
    Unno, Rei
    Taguchi, Kazumi
    Hamamoto, Shuzo
    Ando, Ryosuke
    Hashita, Tadahiro
    Tozawa, Keiichi
    Matsunaga, Tamihide
    Kohri, Kenjiro
    Yasui, Takahiro
    JOURNAL OF UROLOGY, 2022, 207 (05): : E68 - E69